Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Martha Stoops

Physician Assistant, Medical Virginia Beach, VA Physician Assistant

NPI 1235765496 CMS profile 11020358

1120 First Colonial Rd Ste 100, Virginia Beach, VA 23454

Open in the dashboard

General payments

$6,987

291 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Martha Stoops of Virginia Beach, VA is reported in the CMS Open Payments database as having received $6,987 across 291 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,748 63
2024 General $1,588 56
2023 General $1,138 63
2022 General $1,205 60
2021 General $1,308 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Martha Stoops
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Martha Stoops were reported at $1,748. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Martha Stoops Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,308 $156 $41–$563 $132
2022 $1,205 $185 $55–$649 $149
2023 $1,138 $199 $58–$717 $160
2024 $1,588 $206 $62–$740 $164
2025 $1,748 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,355 104 payments
  2. Novo Nordisk Inc $394 14 payments
  3. Ardelyx, Inc. $381 10 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $353 18 payments
  5. Celgene Corporation $332 24 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $327 20 payments
  7. Phathom Pharmaceuticals, Inc. $288 5 payments
  8. Regeneron Healthcare Solutions, Inc. $281 9 payments
  9. AstraZeneca Pharmaceuticals LP $267 3 payments
  10. Janssen Biotech, Inc. $249 10 payments
  11. Other $1,759 74 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,966 290 payments
  2. Education $21 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $1,426 63 payments
  2. SKYRIZI Immunology $629 28 payments
  3. SKYRIZI Immunology $591 24 payments
  4. IBSRELA $381 10 payments
  5. ENTYVIO $353 18 payments
  6. ZEPOSIA $315 22 payments
  7. STELARA $279 9 payments
  8. RYBELSUS $270 11 payments
  9. VOQUEZNA $264 3 payments
  10. UBRELVY $259 14 payments
  11. Other $4,211 191 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

373

Median for Physician Assistant: 241

Drug cost

$5,992

Median for Physician Assistant: $4,110

Branded share of claims

19.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pantoprazole Sodium Generic 88 $1,545
Vancomycin Hcl Generic 11 $1,033
Omeprazole Generic 86 $841
Famotidine Generic 71 $652
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 34 $527
Ondansetron Odt Ondansetron Brand 24 $397
Esomeprazole Magnesium Generic 11 $342
Ondansetron Hcl Generic 12 $247
Dicyclomine Hcl Generic 21 $238
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 15 $171

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$32,252

Medicare's payments for the services billed

Medicare patients

317

Average age 73

Services billed

485

192 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 37%
Ischemic heart disease 25%
Depression 25%
Chronic kidney disease 21%
Heart failure 18%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $370
$370 — —
SKYRIZI
  • AbbVie, Inc. $349
$349 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $271
$271 — —
GIMOTI
  • EVOKE PHARMA, INC. $124
$124 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

291 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record